Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
EU health regulator urges immediate vaccinations amid early surge in flu cases - 2Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- 3The Way to Business: Startup Illustrations Learned
- 4Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- 5The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Sources: IDF does not actually know how many ballistic missiles Iran has left
- Famous Places to get-away for Americans
- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- Very good quality Greens All over The Planet
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- From Loner to Force to be reckoned with: Individual Accounts of Change
- New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
